Xsensio raises USD 7M Series A for clinical rollout
03.03.2026
Zurich-based deep-tech company Xsensio SA has closed an oversubscribed USD 7 million Series A financing round to accelerate the clinical development and validation of its Lab-on-Skin wearable biosensing technology. The funding supports the company’s ambition to bring near real-time, continuous biochemical monitoring into hospital settings and broader healthcare applications.
 |
 |
Xsensio develops a wearable platform designed to deliver continuous biochemical data for personalized and preventive care. Its Lab-on-Skin technology integrates ultra-miniaturized sensors on a single chip, enabling multiparametric analysis of biomarkers ranging from metabolites and ions to proteins and hormones. The modular architecture allows the platform to be configured for different clinical use cases, offering flexibility across patient populations and therapeutic areas.
The USD 7 million Series A round was led by WI Harper, with participation from Privilège Ventures, the European Innovation Council, and private investors from the United States, Europe, and Asia. The financing will support further product development, clinical validation studies, and preparations for large-scale deployment.
In parallel with the financing, Xsensio, a Venture Kick winner and Top100 Swiss Startup, announced a long-term collaboration with Texas Instruments. The partnership focuses on CMOS integration, advanced miniaturization, and scalable manufacturing of biosensing systems. By combining semiconductor expertise with its biochemical sensing platform, Xsensio aims to strengthen industrial scalability and accelerate the transition from development to clinical adoption.
Esmeralda Megally and Adrian Ionescu, Xsensio co-founders
The USD 7 million Series A round was led by WI Harper, with participation from Privilège Ventures, the European Innovation Council, and private investors from the United States, Europe, and Asia. The financing will support further product development, clinical validation studies, and preparations for large-scale deployment.
In parallel with the financing, Xsensio, a Venture Kick winner and Top100 Swiss Startup, announced a long-term collaboration with Texas Instruments. The partnership focuses on CMOS integration, advanced miniaturization, and scalable manufacturing of biosensing systems. By combining semiconductor expertise with its biochemical sensing platform, Xsensio aims to strengthen industrial scalability and accelerate the transition from development to clinical adoption.
Esmeralda Megally and Adrian Ionescu, Xsensio co-founders